Nkarta CEO Paul Hastings at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)

Nkar­ta breaks si­lence on CAR-NK ther­a­py for AML af­ter a year, shares tum­ble

Nkar­ta hopes us­ing a dif­fer­ent chemother­a­py reg­i­men ahead of dos­ing its CAR-NK cell ther­a­py will lead to bet­ter re­sults in acute myeloid leukemia pa­tients whose …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.